SGX301 (synthetic hypericin) is a first-in-class potent photosensitizer which utilizes safe visible light for activation. Hypericin is also found in several species of Hypericum plants, although the drug used in SGX301 is chemically synthesized by a proprietary manufacturing process and not extracted from plants. Importantly, hypericin is optimally activated by visible light, avoiding the negative consequences of ultraviolet light used by other photodynamic therapies.
Soligenix is advancing the development of SGX301 for the treatment of cutaneous T-cell lymphoma (CTCL) with the objective of initiating a Phase 3 clinical study in 2015.
SGX94 (susquetide) is a first-in-class proprietary drug with a novel mechanism of action. SGX94 is an innate defense regulator (IDR) which can be used to offset dysfunctional innate immune responses, such as those that occur in oral mucositis, and aid in the resolution of infection. Susquetide is a fully synthetic, 5-amino acid peptide with high aqueous solubility and stability. Soligenix has a strong intellectual property portfolio around SGX94 and related analogs, including composition of matter and therapeutic use.
Soligenix is currently developing SGX942 for oral mucositis in head and neck cancer and SGX943 in Melioidosis.
Beclomethasone 17,21-dipropionate (BDP) is a highly potent, topically active corticosteroid with a local effect on inflamed tissue. BDP has been marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredient in a nasal spray and in a metered-dose inhaler for the treatment of allergic rhinitis and asthma in both adults and children. The rationale for its administration is that it provides a potent topical anti-inflammatory effect with less systemic toxicity than a comparably effective systemic corticosteroid.
Soligenix has several proprietary products designed to take advantage of the topical activity of BDP for the treatment of gastrointestinal inflammation: SGX201, and SGX203.